- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
- Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges
- A Possible Reversible Cause of Cognitive Impairment: Undiagnosed Cirrhosis and Potential Hepatic Encephalopathy in Patients with Dementia
- Global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium
- Diagnostic Ability of Simple Noninvasive Blood Tests to Predict Increased Liver Stiffness in People Living With HIV and Steatotic Liver Disease
- BiliQML: a supervised machine-learning model to quantify biliary forms from digitized whole slide liver histopathological images
- Burden of Portal Hypertension Complications Is Greater in Liver Transplant Wait-Listed Registrants with End-Stage Liver Disease and Type 2 Diabetes
School of Medicine
Research
We are at the forefront of developing new treatments and therapies to stop, prevent and reverse liver disease
With a patient-centered approach, the Stravitz-Sanyal Institute will transform lives through translational science. Our team of highly specialized physician-scientists conducts cutting-edge investigations through bench research and clinical trials across a broad spectrum of diseases and conditions related to the liver.
Explore our researchers’ publications in the following areas:
- Alcohol-induced hepatitis
- Alcohol-induced liver disease
- Biliary atresia
- Cholestatic disorders
- Cirrhosis
- Complications of liver disease
- Decompensating liver disease
- Hepatitis B
- Hepatitis C
- Hepatocellular carcinoma (HCC)
- Hepato-renal syndrome (HRS)
- Liver transplant
- Metabolic disease (e.g., diabetes, hypertension, obesity)
- Metabolic dysfunction-associated steatotic liver disease (MAFLD), formerly known as NAFLD
- Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH
- Primary biliary cholangitis (PBC)
- Primary sclerosing cholangitis (PSC)
As the institute grows, our next step is to apply gene manipulation therapy, a modern medical breakthrough, to bedside treatment for the liver without invasive surgery or medication. This advancement will have immediate benefits to patients here in the Richmond area and impact how we understand and treat the liver worldwide.
Featured Publications
Jennifer Sayne, Ph.D., director of the institute’s expanding biorepository
Current enrolling clinical trials
To learn more about clinical trials currently enrolling participants, visit VCU Health's Research and Clinical Trials webpage.
Current NIH-funded grants
To learn more about ongoing NIH-funded grants, select a team member below:
Support our research
Private donations empower top researchers to explore creative solutions. Sign our love letter to the liver by contributing to the Stravitz-Sanyal Institute.